non-cystic fibrosis bronchiectasis - Search News

News

FDA, bronchiectasis

UPI on MSN · 3d

First drug to treat bronchiectasis lung condition approved by FDA

The U.S. Food and Drug Administration has approved Insmed's daily bronchiectasis pill, brensocatib, which will be sold under the brand name Brinsupri.

FDA approves brensocatib for non-cystic fibrosis bronchiectasis

The FDA granted approval to brensocatib for treating adults and children aged at least 12 years with non-cystic fibrosis bronchiectasis, marking the first treatment approved for this indication, according to a press release from Insmed.

Clinical Advisor · 2d

Brinsupri Approved for Non-Cystic Fibrosis Bronchiectasis

The Food and Drug Administration (FDA) has approved Brinsupri ™ (brensocatib) for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients aged 12 years and older.

Stocktwits on MSN3d

HC Wainwright Doubles Price Target On Insmed After Brinsupri Approval: Retail Expects Stock To Hit $150 By End Of Week

H.C. Wainwright on Wednesday doubled its price target on Insmed (INSM) to $240 from $120 while keeping a ‘Buy’ rating on the ...

Pharmaceutical Technology4d

Fosun and Expedition make $645m licensing deal for respiratory drug

Fosun Pharma Industrial has entered a licence agreement to grant ex-China rights for its respiratory drug, XH-S004, to Expedition.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results